文献速递泌尿男性生殖肿瘤

晚期肾细胞癌系统治疗格局的演变

Evolving Systemic Treatment Landscape for Patients With Advanced Renal Cell Carcinoma.
PubMed 文献 · J Clin Oncol · 2018-10-29

本文聚焦晚期肾细胞癌系统治疗的标志性随机对照试验,梳理联合治疗、初治与经治患者用药、序贯策略及给药方案。VEGF靶向与免疫检查点治疗已取代细胞因子成为标准,卡博替尼、纳武利尤单抗及双药联合正在改变治疗范式,但晚期RCC仍大多不可治愈。

要点

  • VEGF靶向与免疫检查点治疗已取代细胞因子成为晚期RCC标准治疗。
  • 纳武利尤单抗联合伊匹木单抗、阿替利珠单抗联合贝伐珠单抗已改变治疗格局。
  • 治疗选择依据体能状态、合并症、预后风险、不良事件谱及给药方式。

核心结论

  • 晚期RCC治疗选择快速演变,但仍是大多不可治愈的疾病,需要更多策略。

研究设计与样本

  • 聚焦性综述,纳入指导晚期RCC系统治疗的关键随机对照试验,关注联合治疗、初治与经治患者、序贯策略及给药方案。

主要发现

  • 过去15年晚期RCC系统治疗取得巨大进展,分子靶向与免疫治疗取代细胞因子成为标准治疗。
  • 既往主流范式为序贯VEGF靶向治疗或VEGF靶向后行mTOR抑制,卡博替尼与纳武利尤单抗对此提出挑战。
  • 纳武利尤单抗联合伊匹木单抗及阿替利珠单抗联合贝伐珠单抗已改变RCC治疗格局,其他双药联合在临床试验中可能继续改变范式。
  • 目前临床尚无预测性生物标志物的I级证据。

关键数值与推荐

  • 治疗选择因素包括体能状态、合并症、预后风险分层、治疗不良事件谱及给药方式。
  • 临床尚无预测性生物标志物使用的I级证据。

临床怎么用

  • 临床选择方案时应综合评估体能状态、合并症、预后风险、不良事件谱及给药方式。
  • 应关注卡博替尼、纳武利尤单抗及双药联合等新方案对传统序贯范式的挑战。

局限性

  • 为聚焦性综述,非系统检索或荟萃分析。
  • 晚期RCC仍大多不可治愈,现有方案疗效有限。
  • 临床尚无预测性生物标志物的I级证据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To outline current practices and challenges in the systemic management of patients with advanced renal cell carcinoma (RCC). DESIGN: We conducted a focused review of hallmark randomized controlled trials informing the systemic treatment of patients with RCC. We concentrated on trials informing the use of combination therapies, therapy in both treatment-naïve and previously treated patients, sequential treatment strategies, and schedules. RESULTS: The systemic treatment of advanced RCC has experienced tremendous progress over the past 15 years. An improved understanding of the canonical pathways implicated in RCC pathogenesis has resulted in the development of molecularly targeted and immunotherapy options for patients. These therapies have replaced cytokine-based treatments as the standard of care for patients with advanced RCC. Until recently, sequential vascular endothelial growth factor (VEGF)-targeted therapy or VEGF-targeted therapy followed by mammalian target of rapamycin inhibition has been the prevailing treatment paradigm for patients. However, newer agents such as cabozantinib and nivolumab have challenged this traditional approach. In addition, combination treatments including nivolumab plus ipilimumab and atezolizumab plus bevacizumab have transformed the RCC treatment landscape, and other doublet combinations in clinical testing will likely continue to alter the treatment paradigm in RCC. Currently, factors that inform treatment selection between different therapy options include performance status, comorbidities, prognostic risk stratification, treatment adverse event profile, and mode of administration, with no Level I evidence for predictive biomarker use in clinic. CONCLUSIONS: The treatment options for advanced RCC are rapidly evolving since the introduction of VEGF-targeted therapy, immunotherapy with checkpoint blockade and, more recently, combination regimens. Despite the success of these regimens, advanced RCC remains a largely incurable disease, and additional strategies are warranted.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. McKay RR, Bossé D, Choueiri TK, et al. Evolving Systemic Treatment Landscape for Patients With Advanced Renal Cell Carcinoma. J Clin Oncol. 2018. PMID: 30372392. doi:10.1200/JCO.2018.79.0253

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。